Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorDr. Diane Lougheed
About this trial
The objectives of this study are to determine the sensory-mechanical responses to Eucapneic Voluntary Hyperventilation (EVH) and Mannitol in individuals with cough variant asthma (CVA) and methacholine-induced cough with normal airway sensitivity (COUGH) and compare these responses to a control group of healthy individuals without asthma or chronic cough.
We hypothesize:
1. EVH and Mannitol cause dyspnea, cough, small airway obstruction with resultant dynamic hyperinflation, gas trapping and autoPEEP in individuals with CVA and COUGH, but not healthy controls. 2. The sensory-mechanical responses to both hyperosmolar challenges (EVH and Mannitol) are comparable within groups (CVA, COUGH and healthy controls).
Eligibility criteria
Qualifiers
CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator);
Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 > 16 mg/mL).
Individuals aged 18-65 years of age with no history of asthma or chronic cough.
Disqualifiers
an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks
inability to perform acceptable spirometry
medical contraindications to methacholine challenge testing
smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion; medication use will be recorded and examined in the analysis.
Trial design
Treatments tested in this trial
- Methacholine (MCh) Challenge Testing
- Eucapneic Voluntary Hyperventilation (EVH)
- Mannitol Inhalation Kit
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Dr. Diane Lougheed
Lead sponsor
Queen's University
Sponsor institution
Source ClinicalTrials.gov